6465-03-8

Basic information

• Product Name: N-(4-Aminophenyl)carbamic acid methyl ester
• Synonyms: N-(4-Aminophenyl)carbamic acid methyl ester;Carbamic acid, (4-aminophenyl)-, methyl ester;Carbamic acid, N-(4-aminophenyl)-, methyl ester;Einecs 229-280-4;Methyl p-aminophenylcarbamate;N-Carbomethoxy-1,4-benzenediamine
• CAS NO: 6465-03-8
• Molecular Formula: C₈H₁₀N₂O₂
• Molecular Weight: 166.1772
• EINECS: 229-280-4
• Mol File: 6465-03-8.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 259.3°Cat760mmHg
• Flash Point: 110.6°C
• Appearance: /
• Density: 1.267g/cm³
• Vapor Pressure: 1.31E-10mmHg at 25°C
• Refractive Index: 1.609
• CAS DataBase Reference: N-(4-Aminophenyl)carbamic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-Aminophenyl)carbamic acid methyl ester(6465-03-8)
• EPA Substance Registry System: N-(4-Aminophenyl)carbamic acid methyl ester(6465-03-8)

Safety Data

• Hazardous Substances Data: 6465-03-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C20H20N2O3S/c1-13(2)25-18-14(8-7-11-16(18)24-3)12-17-19(23)22-20(26-17)21-15-9-5-4-6-10-15/h4-13H,1-3H3,(H,21,22,23)

Upstream product

• 1943-87-9 methyl N-(4-nitrophenyl)carbamate 
• 100-01-6 4-nitro-aniline 
• 222400-05-7 methyl N-(p-nitrosophenyl)carbamate 
• 71026-66-9 N-(tert-butoxycarbonyl)-1,4-phenylenediamine 
• 1430115-43-7 1-Boc-methyl 4-aminophenylcarbamate 
• 100-28-7 4-Nitrophenyl isocyanate 
• 67-56-1 methanol 
• 2603-10-3 N-phenyl methyl carbamate 
• 79-22-1 methyl chloroformate 
• 122-80-5 N-acetyl-p-phenylenediamine 
• 100-25-4 para-dinitrobenzene 
• 201230-82-2 carbon monoxide 

Downstream Products

• 1309945-86-5 C₂₀H₂₀N₄O₄ 
• 1430115-44-8 methyl 4-formamidophenylcarbamate 
• 1094106-63-4 [4-((S)-2-tert-butoxycarbonylamino-3-phenyl-propionylamino)phenyl]carbamic acid methyl ester 
• 1430562-68-7 C₃₉H₃₇ClFN₉O₅ 
• 1430115-42-6 methyl 4-isocyanophenylcarbamate 
• 1224596-16-0 C₁₈H₁₈N₄O₄ 

Relevant articles and documents

Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors

We are concerned with the development of novel anti-infectives with dual antibacterial and antiretroviral activities for MRSA/HIV-1 co-infection. To achieve this goal, we exploited for the first time the mechanistic function similarity between the bacterial RNA polymerase (RNAP) "switch region" and the viral non-nucleoside reverse transcriptase inhibitor (NNRTI) binding site. Starting from our previously discovered RNAP inhibitors, we managed to develop potent RT inhibitors effective against several resistant HIV-1 strains with maintained or enhanced RNAP inhibitory properties following a structure-based design approach. A quantitative structure-activity relationship (QSAR) analysis revealed distinct molecular features necessary for RT inhibition. Furthermore, mode of action (MoA) studies revealed that these compounds inhibit RT noncompetitively, through a new mechanism via closing of the RT clamp. In addition, the novel RNAP/RT inhibitors are characterized by a potent antibacterial activity against S. aureus and in cellulo antiretroviral activity against NNRTI-resistant strains. In HeLa and HEK 293 cells, the compounds showed only marginal cytotoxicity.

SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS

The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.

SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS

The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.